Treatments:Cancer
From Proteopedia
(Difference between revisions)
												
			
			| Line 53: | Line 53: | ||
* [[Tasigna]] - Generic: [[Nilotinib]]  | * [[Tasigna]] - Generic: [[Nilotinib]]  | ||
* [[Ibrutinib]] - brand name: [[Imbruvica]]  | * [[Ibrutinib]] - brand name: [[Imbruvica]]  | ||
| - | See [[Treatment of chronic myelogenous leukemia]], [[Treatment of hepatocellular carcinoma]] and [[Treatment of gastrointestinal stromal tumor]]  | + | See [[Treatment of chronic myelogenous leukemia]], [[Treatment of hepatocellular carcinoma]], [[Treatment of enal cell carcinoma]]  and [[Treatment of gastrointestinal stromal tumor]]  | 
=====[[Vascular Endothelial Growth Factor]] Inhibitor=====  | =====[[Vascular Endothelial Growth Factor]] Inhibitor=====  | ||
* [[Avastin]] - Generic: [[Bevacizumab]]  | * [[Avastin]] - Generic: [[Bevacizumab]]  | ||
Revision as of 09:32, 8 January 2025
Anti-CD20 Monoclonal Antibody
 Anti-melanoma Monoclonal Antibody
 See Treatment of multiple myeloma Anti-prostate cancer
 Anti-myeloma
 Anti-acute lymphocytic leukemia
 Anti-non-small cell lung cacinoma
 B-Raf Kinase Inhibitor
 ChemotherapyDihydrofolate Reductase Inhibitor
 Epidermal Growth Factor Receptor Inhibitors
 Estrogen Receptor Modulator
 mTOR inhibitor
 Multiple Receptor Tyrosine kinase (VEGFR, PDGFR, EGFR, KIT, Abl, RAF kinase) Inhibitors
 See Treatment of chronic myelogenous leukemia, Treatment of hepatocellular carcinoma, Treatment of enal cell carcinoma and Treatment of gastrointestinal stromal tumor Vascular Endothelial Growth Factor Inhibitor
 Poly ADP ribose polymerase (PARP) inhibitorsCyclin-dependent kinases inhibitors
 See also Anti-cancer drugs, Anticancer drugs and RAF kinase inhibitors  | 
Proteopedia Page Contributors and Editors (what is this?)
David Canner, Michal Harel, Alexander Berchansky, Karsten Theis
